Trial Profile
A randomized Phase II study of Carboplatin + Pemetrexed followed by Pemetrexed versus Carboplatin+Pemetrexed followed by Erlotinib in patients with advanced Non-squamous and Non- Small Cell Lung Cancer without EGFR mutations
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 Jul 2019
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Erlotinib (Primary) ; Pemetrexed (Primary)
- Indications Non-small cell lung cancer
- Focus Biomarker; Therapeutic Use
- 06 Jan 2017 Status changed from recruiting to active, no longer recruiting.
- 08 Jul 2013 New trial record